Markers for detection of gastric cancer
AssigneePacific Edge Limited
InventorParry John Guilford
Life of this patent
Estimating the term…
Abstract
Early detection of tumors is a major determinant of survival of patients suffering from tumors, including gastric tumors. Members of the GTM gene family can be differentially expressed in gastric tumor tissue, and thus can be used as markers for the detection of gastric and other types of cancer. The present invention provides for novel GTMs for the detection of tumors, including gastric tumors, and in particular human zymogen granule protein 16 (ZG16). The GTMs can be used in isolation or together with other known GTMs to provide for novel signatures to be used in the detection of tumors, including gastric tumors.
Claims13
A method for detecting gastric cancer, comprising:
- (i) providing a sample of serum from a human being suspected of having gastric cancer;
- (ii) providing samples of serum from a group of control human beings not having gastric cancer;
- (iii) detecting the levels of zymogen granule protein 16 (“ZG16”) and mucin 17 (“MUC17”) in said sample in step (i) using rolling circle amplification;
- (iv) detecting the levels of a gastric cancer markers (“GTM”) zymogen granule protein 16 (“ZG16”) and MUC17 in said sample in step (ii) using rolling circle amplification, and normalizing expression data;
- (v) normalizing expression data obtained in step (iii) using quintile normalization;
- and
- (vi) comparing the expression of ZG16 and MUC17 in said sample in step (i) with the expression of ZG16 and MUC17 in step (ii),
- wherein an increase of normalized ZG16 expression and an increase of normalized MUC17 expression in the sample of serum from said human being compared to the normalized expression of ZG16 and MUC17 in a group of control samples of serum is indicative of gastric cancer.
Dependencies are inferred from the claim text.